Skip to main content
. Author manuscript; available in PMC: 2019 Apr 19.
Published in final edited form as: ACS Chem Biol. 2019 Mar 12;14(4):751–757. doi: 10.1021/acschembio.9b00032

Figure 4.

Figure 4.

Pharmacokinetic profile of the investigational prodrug PPD. Plasma concentration of PPD (ID = 2 mg/kg, formulated at 500 μM) administered as (A) colloids (0.04% PLAC–PEG) or (B) solubilized monomer (5% UP80). Trend line denotes exponential decay fitting of the lambda elimination phase. (C) Pharmacokinetic parameters of noncompartmental analysis show improvement in colloidal PPD half-life due to decreased clearance, resulting in increased AUC (n = 3–6, mean + SD).